ASSOCIATE PROFESSOR OF MEDICINE, DIRECTOR OF CLINICAL AND TRANSLATIONAL RESEARCH
Washington University School of Medicine
St. Louis, Missouri
Parakkal Deepak, MBBS, MS, FACG is currently a physician-scientist in the Inflammatory Bowel Disease (IBD) Center in the Division of Gastroenterology at the Washington University School of Medicine (WUSM) in St. Louis, Missouri where he is an Associate Professor of Medicine and Director of Clinical and Translation research. He is a Fellow of ACG and has been recognized as an ‘AGA Future Leader’ by the American Gastroenterological Association. He has been funded by the American College of Gastroenterology Junior Faculty Development Award, the American Gastroenterological Association, and The Leona M. and Harry B. Helmsley Charitable Trust apart from investigator-initiated grants funded by industry. His group’s primary focus is on fistulizing perianal Crohn’s disease where he co-leads a bench-bedside basic-translational-clinical group focused on improving the precision of care in perianal CD through single-cell work, radiomics, and 3D print applications and is part of the international TOpCLASS fistula consortium. Additional focus area in research is cardiometabolic syndrome in IBD where his group has made novel observations in the prevalence of NAFLD, risk of cirrhosis, and performance of current ASCVD prediction tools in patients with IBD. He has co-founded the REBOOT IBD consortium across 11 leading IBD centers in the United States to publish real-world data on outcomes with the newest advanced therapies in IBD. He serves as the Deputy Director of Data Quality and Enhancement of the prospective longitudinal biobanking cohort, the SPARC-IBD of the Crohn’s and Colitis Foundation, and on the National Scientific Advisory Committee of the Crohn’s and Colitis Foundation. He also serves as a section councilor for the Immunology, Microbiology & Inflammatory Bowel Diseases (IMIBD) section of the AGA Institute Council.
Sp32 - Lunch and Table Discussions
Thursday, February 6, 2025
11:30 AM - 12:30 PM PST
Sp33 - Table Discussion: CD Positioning - First Treatment Options
Thursday, February 6, 2025
12:30 PM - 1:20 PM PST
Thursday, February 6, 2025
1:20 PM - 1:35 PM PST
Sp43 - Table Discussion: UC Positioning - Treatment Experienced Options
Thursday, February 6, 2025
2:30 PM - 3:30 PM PST
9 - IL-23-ACTIVATED CELLS PREDICT RESPONSE TO RISANKIZUMAB IN CROHN'S DISEASE
Saturday, February 8, 2025
8:00 AM - 8:10 AM PST
10 - IRE1A-XBP1 CONTROLS INNATE LYMPHOID CELLS AND COLITIS-INDUCED FIBROSIS
Saturday, February 8, 2025
8:10 AM - 8:20 AM PST